Transcatheter aortic valve replacement is cost effective compared with surgical replacement for low-risk patients
Advanced photon source helps Pfizer create COVID-19 antiviral treatment
8 November 2021Tips to help make getting a COVID-19 vaccine less scary for kids
8 November 2021Transcatheter aortic valve replacement is cost effective compared with surgical replacement for low-risk patients
An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.
